Table 1. CD20: A new angle of attack. A study by a multinational team suggests that depleting B cells with anti-CD20 therapy shortly after myocardial infarction (MI) could reduce infarct size and improve cardiac function, thereby reducing the risk of death or recurrent MI. The findings offer a repurposing opportunity to companies that market or are developing anti-CD20 antibodies to treat cancer, autoimmune diseases and inflammatory indications. Additionally, at least eight other companies market or are developing biosimilars of the anti-CD20 antibody rituximab to treat cancer and autoimmune indications.

Source: BCIQ: BioCentury Online Intelligence


Anti-CD20 antibodyA

Antibody type


Biogen Idec Inc. (NASDAQ:BIIB)/Roche (SIX:ROG; OTCQX:RHHBY)/Genentech Inc.

Rituxan/MabThera rituximab

Chimeric mAb

Marketed for chronic lymphocytic leukemia (CLL), lymphoma, non-Hodgkin's lymphoma (NHL), inflammatory disease, multiple sclerosis (MS) and rheumatoid arthritis (RA); Phase III to treat mantle cell lymphoma (MCL)

Genmab A/S (CSE:GEN;OTCBB:GMXAY)/GlaxoSmithKline plc (LSE:GSK; NYSE:GSK)

Arzerra ofatumumab

Human mAb

Marketed for CLL; Phase III for B cell lymphoma, NHL, pemphigus vulgaris (PV) and RA; Phase II for MS

Roche/Genentech/Chugai Pharmaceutical Co. Ltd. (Tokyo:4519)/Nippon Shinyaku Co. Ltd. (Tokyo:4516; Osaka:4516)

Obinutuzumab (GA101; RG7159; RO5072759)

Glycoengineered, humanized mAb

In registration for CLL; Phase III for B cell lymphoma and NHL

Roche/Chugai Pharmaceutical/Genentech/Halozyme Therapeutics Inc. (NASDAQ:HALO)

Subcutaneous rituximab

Chimeric mAb

In registration for NHL

Biogen Idec/Roche/Genentech

Ocrelizumab (R1594; RG1594)

Humanized mAb

Phase III for MS

Immunomedics Inc. (NASDAQ:IMMU)/Takeda Pharmaceutical Co. Ltd. (Tokyo:4502)

Veltuzumab (hA20; IMMU-106)

Humanized mAb

Phase II for lupus; Phase I/II for CLL, NHL, hematological malignancies and idiopathic thrombocytopenic purpura (ITP); preclinical for pancreatic cancer

LFB S.A./Ildong Pharmaceutical Co. Ltd. (KSE:000230)/TG Therapeutics Inc. (NASDAQ:TGTX)

Ublituximab (LFB-R603;
TG-1101; TGTX-1101)

Chimeric mAb

Phase I/II for B cell lymphoma, CLL and NHL

Biocon Ltd. (NSE:BIOCON; BSE:BIOCON)/Vaccinex Inc.


Humanized mAb

Phase I for NHL

ADoes not include anti-CD20 antibodies that are radiolabeled, bispecific or multivalent.